Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,040.00 +3.46 (+0.33%)
Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
The $1 Trillion Apothecary: A Deep-Dive Research Report on Eli Lilly (LLY)
As of February 5, 2026, Eli Lilly and Company (NYSE: LLY) stands as a paradigm-shifting titan in the global healthcare landscape. Having recently crossed the historic $1 trillion market capitalization... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles ↗
Via MarketBeat
News headline image
Expert Outlook: Eli Lilly and Co Through The Eyes Of 15 Analysts ↗
 
Via Benzinga
News headline image
Eli Lilly Shares Boosted BY GLP-1s ↗
On Wednesday, Eli Lilly reported earnings well above expectations, and its shares initially rose by 10%. 
Via Talk Markets
Eli Lilly & Co (NYSE:LLY) Stands Out in Recent CANSLIM Growth Stock Screen ↗
Via Chartmill
Eli Lilly Stock Notches Best Day In 9 Months: Touts $50 Medicare For Obesity Drugs As ‘Compelling Value Proposition’ After Q4 Beat ↗
Via Stocktwits
Eli Lilly & Co. (NYSE:LLY) Soars on Blockbuster Q4 Earnings and Upbeat 2026 Guidance ↗
Via Chartmill
News headline image
Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party? ↗
Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can. 
Via The Motley Fool
News headline image
LLY Q4 Deep Dive: Obesity Medicines, Pipeline Progress, and Market Expansion Drive Outperformance
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 42.6% year on year to $19.29 billion. The company’s full-year... 
Via StockStory
News headline image
Why Eli Lilly Stock Soared Today ↗
The healthcare giant gained nearly $100 billion in market value. 
Via The Motley Fool
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
In Weight Loss Drug Battle For 2026, Eli Lilly Pulls Ahead Of Novo Nordisk ↗
Novo Nordisk shares slide after weak 2026 guidance, while Eli Lilly rallies on strong earnings, booming weight loss drug sales, and a broader pipeline advantage. 
Via Benzinga
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Nasdaq Dips Over 400 Points; Eli Lilly Shares Surge Following Upbeat Earnings ↗
 
Via Benzinga
News headline image
Eli Lilly Q4 2025 Earnings Call Transcript ↗
Eli Lilly and Company (NYSE:LLY) reported fourth-quarter financial results on Wednesday. The transcript from the earnings call has been provided below. 
Via Benzinga
Topics Earnings
News headline image
Eli Lilly (LLY) Stock Trades Up, Here Is Why
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 10% in the afternoon session after the company reported fourth-quarter 2025 results that beat Wall Street expectations and issued an... 
Via StockStory
News headline image
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗
Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board. 
Via The Motley Fool
News headline image
Eli Lilly (LLY) Q4 2025 Earnings Call Transcript ↗
Eli Lilly (LLY) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance ↗
Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is... 
Via Stocktwits
Topics Intellectual Property
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Q4 Earnings Summary: Eli Lilly And AbbVie Beat, Uber Mixed ↗
Quarterly earnings reveal a mix of positive surprises and challenges, with Eli Lilly and AbbVie beating expectations and Uber facing hurdles. 
Via Talk Markets
News headline image
Eli Lilly Surges 9% After Obliterating Forecasts As Mounjaro, Zepbound Sales Double ↗
The drugmaker smashed Q4 expectations and guided up on its obesity treatments. 
Via Investor's Business Daily
News headline image
LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗
Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data. 
Via Stocktwits
News headline image
Eli Lilly (NYSE:LLY) Reports Strong Q4 CY2025, Stock Soars
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 42.6% year on year to $19.29 billion. The company’s full-year... 
Via StockStory
News headline image
Does Stanley Druckenmiller Know Something Wall Street Doesn't? He Dumped All of His Shares in a Company Dominating a Market That May Soon Be Worth $100 Billion and Opened Positions in 3 AI Giants. ↗
Druckenmiller has renewed his AI bet. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Novo Nordisk Vs Eli Lilly: Which Big Pharma Stock Has More Upside This Year Amid Earnings Season? ↗
Novo leads early in oral obesity drugs, while Lilly counters with a strong injectable franchise and an oral pill nearing approval. 
Via Stocktwits
Topics Intellectual Property
News headline image
Eli Lilly Is Getting Into the Hearing Loss Market in a $1.12 Billion Deal With Seamless Therapeutics ↗
While riding high on the popularity of its weight loss drug Zepbound, the company is quietly building a presence in a cutting-edge healthcare segment. 
Via The Motley Fool
News headline image
Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook ↗
Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments. 
Via The Motley Fool
Topics Initial Public Offering Intellectual Property Stocks
News headline image
The Smartest Growth Stock to Buy With $30 Right Now ↗
This pre-revenue biopharmaceutical stock is a home run swing worth taking. 
Via The Motley Fool
News headline image
As Novo Nordisk Stock Breaks Below Key Support Levels, Should You Buy the Dip?
Novo Nordisk stock sank as management forecasts decelerating growth in 2026. But should you treat this selloff in NVO shares as a buying opportunity? Let’s find out. 
Via Barchart.com
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.